Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat in ECMO
NCT06676085Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of Nafabelltan in respiratory failure (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Incidence of ECMO related bleeding or thrombotic events at 28 days. Started May 2025; status: recruiting.
02
Drugs
Nafabelltan
03
Conditions
respiratory failure
Beyond the preview
Go deeper on NCT06676085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676085.